Rafferty Asset Management LLC Boosts Stake in ACADIA Pharmaceuticals Inc. $ACAD

Rafferty Asset Management LLC boosted its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 55.1% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 195,031 shares of the biopharmaceutical company’s stock after acquiring an additional 69,294 shares during the quarter. Rafferty Asset Management LLC’s holdings in ACADIA Pharmaceuticals were worth $4,162,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of ACAD. PNC Financial Services Group Inc. grew its holdings in shares of ACADIA Pharmaceuticals by 11.2% during the third quarter. PNC Financial Services Group Inc. now owns 5,323 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 534 shares in the last quarter. Thrivent Financial for Lutherans lifted its position in ACADIA Pharmaceuticals by 0.7% during the second quarter. Thrivent Financial for Lutherans now owns 91,067 shares of the biopharmaceutical company’s stock valued at $1,964,000 after purchasing an additional 626 shares during the last quarter. GAMMA Investing LLC lifted its position in ACADIA Pharmaceuticals by 25.8% during the third quarter. GAMMA Investing LLC now owns 3,361 shares of the biopharmaceutical company’s stock valued at $72,000 after purchasing an additional 690 shares during the last quarter. Geneos Wealth Management Inc. increased its holdings in shares of ACADIA Pharmaceuticals by 113.0% in the 3rd quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 756 shares during the last quarter. Finally, Smartleaf Asset Management LLC raised its position in shares of ACADIA Pharmaceuticals by 107.0% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,712 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 885 shares in the last quarter. Hedge funds and other institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Stock Down 1.4%

Shares of NASDAQ ACAD opened at $22.50 on Wednesday. The firm’s fifty day moving average is $25.32 and its 200 day moving average is $24.40. ACADIA Pharmaceuticals Inc. has a 52 week low of $13.40 and a 52 week high of $28.35. The company has a market cap of $3.84 billion, a price-to-earnings ratio of 9.83, a PEG ratio of 18.95 and a beta of 0.66.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $1.48. ACADIA Pharmaceuticals had a net margin of 36.49% and a return on equity of 12.49%. The business had revenue of $298.00 million for the quarter, compared to analyst estimates of $292.54 million. During the same quarter last year, the firm earned $0.86 EPS. The company’s revenue was up 9.4% on a year-over-year basis. Equities research analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.7 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently commented on ACAD. Needham & Company LLC reissued a “buy” rating and issued a $34.00 target price on shares of ACADIA Pharmaceuticals in a research note on Monday, January 5th. UBS Group upped their price objective on ACADIA Pharmaceuticals from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of ACADIA Pharmaceuticals in a report on Monday. Citigroup upped their target price on ACADIA Pharmaceuticals from $33.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Finally, Wolfe Research assumed coverage on shares of ACADIA Pharmaceuticals in a research report on Monday, February 23rd. They set an “outperform” rating and a $33.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $31.05.

More ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Wolfe Research initiated coverage with an Outperform rating and a $33 price target, highlighting conviction-driven opportunities across ACADIA’s neuroscience franchises — a near-term catalyst for investor optimism. Wolfe Research Notes Conviction-Driven Opportunities in ACADIA Pharmaceuticals Inc.’s (ACAD) Therapeutic Domains
• Positive Sentiment: ACADIA appointed Jonathan M. Poole to its board (joining the Audit Committee). His biotech finance and corporate leadership experience may strengthen governance and investor confidence. Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
• Neutral Sentiment: ACADIA announced it will request CHMP re-examination after a negative CHMP opinion on trofinetide for Rett syndrome — a standard regulatory next step that preserves the chance of approval but leaves near-term uncertainty. Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
• Neutral Sentiment: Some outlets report an average analyst rating of “Moderate Buy” for ACAD, reflecting mixed but generally constructive sell‑side sentiment; these consensus views can limit downside but aren’t immediate catalysts. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Average Rating of “Moderate Buy” by Analysts
• Neutral Sentiment: Reported short‑interest entries appear to show zero shares / NaN changes (data glitch); there’s no clear short‑squeeze signal from these reports — treat short‑interest data as unreliable until corrected.
• Negative Sentiment: European regulators (CHMP/EMA) recommended against approval of trofinetide for Rett syndrome, which is a clear near‑term negative: it reduces the likelihood of European revenue for the drug absent a successful re‑examination. European Regulators Recommend Against Acadia’s Application for Rett Syndrome Treatment
• Negative Sentiment: HC Wainwright published a pessimistic near‑term outlook for ACAD’s Q1 earnings, which can amplify selling pressure if investors fear guidance misses or margin risk. HC Wainwright Has Pessimistic Outlook of ACAD Q1 Earnings

Insider Activity

In related news, EVP Jennifer J. Rhodes sold 6,950 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $23.38, for a total transaction of $162,491.00. Following the transaction, the executive vice president owned 7,609 shares in the company, valued at $177,898.42. The trade was a 47.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 28.30% of the stock is owned by insiders.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.